Multiple sclerosis therapy enters phase 2

| Print |  Email
Articles - January 2013
Monday, December 10, 2012

 

BY LINDA BAKER

0113 GamePlan ArtielleMultiple sclerosis is an immune disorder in which the body mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. The resulting neurological symptoms can range from numbness and tingling to paralysis. Although existing therapies reduce inflammation caused by MS, researchers have long sought to develop a therapy that will actually repair the neurological damage.

Enter Artielle ImmunoTherapeutics, a Portland biotech company that will launch an FDA phase-two clinical trial this year for a new therapy researchers say appears to also reverse the dysregulation of the immune system associated with MS and promotes nerve regeneration. The company takes its name from a phonetic rendering of its proprietary technology — recombinant T-cell receptor ligands.

“There is recovery from the disease,” says Arthur Vandenbark, a founding Artielle scientist and a neurology researcher affiliated with the Portland VA Medical Center and Oregon Health & Science University. “That’s what’s so exciting.” The phase-two trial is considered a critical milestone, as it will show the drug can work in MS patients — and not just in animal models. A phase-one trial, indicating the drug’s safety, was completed a few years ago. According to OHSU’s tech-transfer office, Artielle represents the first OHSU drug discovery to be commercialized this far in the clinical trial process by a company that was formed and has remained in Oregon.

Oregon can be a tough environment for homegrown biotech companies, which often struggle to locate investment capital. Founded eight years ago, Artielle is one of the success stories. It has raised $25 million of venture capital, including $2 million from Northwest Technology Ventures and Reference Capital Management, both located in Portland, and $11 million from Sanderling Ventures in the Bay Area, where Artielle CEO Peter McWilliams is based.

The phase-two trial is funded by the Department of Veterans Affairs and will help Artielle achieve its next financial goal: a buyout or partnership with a pharmaceutical company to help bring the product to market.

Only one in about 5,000 biotech startups develops a commercial drug, but the Artielle team thinks they have a shot. The market is saturated with purely anti-inflammatory drugs, says McWilliams. But Artielle’s technology goes further. “This is a disease-modifying agent,” he says.

 

Comments   

 
Guest
0 #1 new ms drugGuest 2013-01-09 19:02:09
what is the main component of the up coming new drug
Quote | Report to administrator
 
 
Guest
-1 #2 infoGuest 2013-02-09 20:49:44
This article gives some info:

http://www.msdiscovery.org/research-resources/drug-pipeline/499-rtl1000

Melanie J
Quote | Report to administrator
 

More Articles

Oregon needs a Grand Bargain energy plan

Linda Baker
Monday, June 22, 2015
0622-gastaxblogthumbBY LINDA BAKER

The Clean Fuels/gas tax trade off will go down in history as another disjointed, on-again off-again approach to city and state lawmaking.


Read more...

Biker dreams

The Latest
Friday, May 15, 2015
bike at ater wynn-thumbBY KIM MOORE | RESEARCH EDITOR

The Portland Bureau of Transportation is seeking input from businesses on a $5.5 million initiative to create a network of biking, transit and pedestrian trails within Portland’s central city.


Read more...

Urban renewer

Linda Baker
Wednesday, June 24, 2015
UnknownBY LINDA BAKER   

One year after he was appointed chair of the Portland Development Commission, Tom Kelly talks about PDC's longevity, Neil Kelly's comeback and his new role as Portlandia's landlord.


Read more...

Apartment Mania

Guest Blog
Thursday, June 18, 2015
4805983977 11466ce1d6 zBY BRAD HOULE | CFA

While most categories of commercial real estate have performed well, one of the most robust has been apartment buildings.


Read more...

6 things to know about the Amtrak Cascades route

The Latest
Friday, May 22, 2015
thumb3BY JACOB PALMER | DIGITAL NEWS EDITOR

The recent tragedy in Philadelphia has called attention to Amtrak and the nation's woefully underfunded rail service. Here are six facts about the Amtrak Cascades corridor between Eugene and Vancouver B.C. 


Read more...

6 key things to know about summer baseball in Oregon

The Latest
Friday, June 05, 2015
basedthumbBY JACOB PALMER | DIGITAL NEWS EDITOR

As temperatures in Oregon creep into the 90s this weekend, Oregonians' thoughts are turning to — summer baseball.


Read more...

Green workplace 2.0

Linda Baker
Thursday, May 28, 2015
IMG 2808BY LINDA BAKER | EDITOR

Reinventing capitalism. Office dumpster divers. Handprints versus carbon footprints.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS